A Phase 1, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics Of Mavodelpar In Subjects With Impaired Hepatic Function

Impaired Hepatic Function The study will enroll as following: · Group 1 (N =10) – Normal hepatic function (healthy subjects), single dose · Group 2 (N=8) – Mild hepatic impairment (Child-Pugh A - a score of 5 to 6), single dose · Group 3 (N=8) – Moderate hepatic impairment (Child-Pugh B a score of 7 to 9), single dose · Group 4 (N=6) – Severe hepatic impairment (Child-Pugh C a score of 10 to 15), single dose Healthy volunteers with normal hepatic function.

No related papers found yet.

None listed

Hungary